Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 2;13(12):2060. doi: 10.3390/pharmaceutics13122060

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

R848 NE and SD-101 treatments of murine colon adenocarcinoma (MC38) syngeneic C57BL/6N mouse model. (A) Timeline for MC38 inoculation and treatment regimen. The mice were inoculated with 0.5 million MC38 subcutaneously on the right flank. Treatments began at 8 days after inoculation when tumors became palpable. Treatments were given every 3 days for up to 4 doses. Mice were euthanized after the fourth dose on day 10. (B–E) Tumor growth over time for individual mice treated with (B) saline, (C) R848 NE, (D) SD-101, or (E) R848 NE/SD-101 combination (n = 5). (F) Images of MC38 tumor tissues were collected at day 10 with measured (G) tumor sizes. (H) Average tumor growth for each treatment group within 10 days. Data are presented as means ± SEM (n = 5). One-way ANOVA: ** p < 0.01, *** p < 0.001.